Yellowstone Biosciences is a startup, 1 tracked investor.
Yellowstone Biosciences is a startup. Brouky records 1 investor associated with the company.
Yellowstone Biosciences develops soluble T-cell receptor (TCR)-based biologic therapies aimed at treating cancers, with a stated focus on acute myeloid leukaemia.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.